sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity

Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators,...

Home / Categories / Healthcare
Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity
Global Multiple Sclerosis Drugs Market...
Report Code
RO1/105/1168

Publish Date
30/Jul/2021

Pages
163
PRICE
$ 3300/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 4700/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 6100/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 87 tables and 87 figures, this 163-page report Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity is based on a comprehensive research of the entire global multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Region.

Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants

Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Monoclonal Antibodies
Interferon Beta
Sphingosine 1 Phosphate Receptor Modulators
Mixed Polymers
NF-?B Inhibitor
Pyrimidine Synthesis Inhibitor
Corticosteroids
Adrenocorticotropic Hormone
Other Drug Classes

Based on Drug Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Large-molecule Drugs
Small-molecule Drugs

Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Oral Administration
Parenteral Administration

Based on MS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Relapsing-remitting MS (RRMS)
Primary-progressive MS (PPMS)
Secondary-progressive MS (SPMS)
Progressive-relapsing MS (PRMS)

Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Geographically, the following regions together with the listed national/local markets are fully investigated:
North America (U.S., Canada, and Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
South America (Brazil, Chile, Argentina, Rest of South America)
MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com